Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ORGO 
Organogenesis Holdings Inc (ORGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ORGO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.04% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 653.32M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 4 | Beta 1.77 | 52 Weeks Range 2.46 - 6.71 | Updated Date 08/29/2025 |
52 Weeks Range 2.46 - 6.71 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.05 | Actual -0.1 |
Profitability
Profit Margin -1.92% | Operating Margin (TTM) -10.72% |
Management Effectiveness
Return on Assets (TTM) -2.01% | Return on Equity (TTM) -2.63% |
Valuation
Trailing PE - | Forward PE 12.32 | Enterprise Value 749034201 | Price to Sales(TTM) 1.52 |
Enterprise Value 749034201 | Price to Sales(TTM) 1.52 | ||
Enterprise Value to Revenue 1.74 | Enterprise Value to EBITDA 234.73 | Shares Outstanding 126858000 | Shares Floating 55469802 |
Shares Outstanding 126858000 | Shares Floating 55469802 | ||
Percent Insiders 46.69 | Percent Institutions 55.13 |
Upturn AI SWOT
Organogenesis Holdings Inc
Company Overview
History and Background
Organogenesis Holdings Inc. was founded in 1985 and is a leading regenerative medicine company focused on developing and commercializing solutions for advanced wound care and surgical and sports medicine. They have grown through organic development and strategic acquisitions.
Core Business Areas
- Advanced Wound Care: Focuses on products for treating chronic and acute wounds, including diabetic foot ulcers, venous leg ulcers, surgical wounds, and burns.
- Surgical and Sports Medicine: Develops and markets products for surgical procedures and sports-related injuries, addressing soft tissue repair and regeneration.
Leadership and Structure
The leadership team consists of seasoned executives with experience in regenerative medicine and healthcare. The organizational structure is designed to support product development, manufacturing, and commercialization efforts.
Top Products and Market Share
Key Offerings
- Apligraf: Apligraf is a bioengineered living cell therapy for the treatment of venous leg ulcers and diabetic foot ulcers. It has a significant market share in the bioengineered skin substitute market. Competitors include Mimedx, Integra LifeSciences, and Smith & Nephew.
- PuraPly AM: PuraPly AM is an antimicrobial barrier matrix indicated for acute and chronic wounds. It is a key product in Organogenesis' advanced wound care portfolio. Competitors include Integra LifeSciences, and Smith & Nephew.
- NuShield: NuShield is a wound covering product made from amniotic membrane, used to protect and heal wounds. Competitors include MiMedx Group, Amniox Medical.
Market Dynamics
Industry Overview
The regenerative medicine industry is experiencing substantial growth driven by the increasing prevalence of chronic wounds, advancements in biotechnology, and growing demand for innovative therapies. There is a strong push for wound care products as the baby boomer generation ages and has more diabetes.
Positioning
Organogenesis is a leading player in the regenerative medicine market, particularly in wound care. Its competitive advantage lies in its diversified product portfolio, strong clinical data, and established sales and marketing infrastructure.
Total Addressable Market (TAM)
The global wound care market is estimated to be worth $22-25 billion. Organogenesis is positioned to address a substantial portion of this market with its diverse product offerings.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong clinical data supporting product efficacy
- Established sales and marketing infrastructure
- Proprietary technology platforms
- Leading position in bioengineered skin substitutes
Weaknesses
- Reliance on reimbursement policies
- Intense competition in the wound care market
- Potential for product recalls
- Sensitivity to changes in healthcare regulations
- In past had issues with sales practice concerns
Opportunities
- Expanding into new geographic markets
- Developing innovative products for unmet medical needs
- Acquiring complementary technologies or businesses
- Partnering with healthcare providers and institutions
- Capitalizing on the growing demand for regenerative medicine
Threats
- Increasing competition from established and emerging players
- Changes in reimbursement policies that could reduce product pricing
- Adverse regulatory changes
- Technological obsolescence
- Economic downturn that could reduce healthcare spending
Competitors and Market Share
Key Competitors
- MIMD
- INTE
- SNY
Competitive Landscape
Organogenesis faces competition from larger, diversified healthcare companies and smaller, specialized regenerative medicine firms. Its competitive advantage lies in its focus on regenerative medicine and wound care.
Major Acquisitions
NuTech Medical
- Year: 2017
- Acquisition Price (USD millions): 85
- Strategic Rationale: Expanded product portfolio and market access in surgical and sports medicine.
Growth Trajectory and Initiatives
Historical Growth: Organogenesis has experienced growth through new products and acquisitions. Past performance is not indicative of future results.
Future Projections: Future growth depends on new product development, market expansion, and strategic partnerships. Analyst estimates should be consulted for specific revenue and earnings projections.
Recent Initiatives: Recent initiatives include product launches, acquisitions, and strategic collaborations designed to expand the company's product portfolio and market reach.
Summary
Organogenesis is a notable player in the regenerative medicine and wound care market with a diversified product portfolio and strong clinical data. However, the company faces intense competition and relies heavily on reimbursement policies. Future growth hinges on successful product development, market expansion, and strategic partnerships. Investors should carefully monitor financial performance and regulatory developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Organogenesis Holdings Inc
Exchange NASDAQ | Headquaters Canton, MA, United States | ||
IPO Launch date 2017-01-05 | President, CEO, Chair of the Board Mr. Gary S. Gillheeney Sr. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 869 | Website https://organogenesis.com |
Full time employees 869 | Website https://organogenesis.com | ||
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.